Immunic Inc (NASDAQ:IMUX) said the results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease are positive,.
Immunic Inc (IMUX) Reports Positive Results from Phase 1b Trial of IMU-856 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib.
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic